Pretzel Therapeutics develops therapies targeting mitochondrial dysfunction by utilizing advanced mitochondrial biology techniques. This approach addresses over 50 diseases linked to genetic mitochondrial disorders, affecting 1 in 5,000 individuals.
Funding
$72.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
MCFounders
Product
Problem
Mitochondrial dysfunction is implicated in a wide range of genetic disorders, affecting a significant portion of the population. These diseases, often caused by mutations in mitochondrial DNA, can manifest in various ways and are challenging to treat. Current therapeutic options are limited, leaving a substantial unmet need for effective interventions.
Solution
Pretzel Therapeutics is developing targeted therapies to address mitochondrial dysfunction at its core. By leveraging advanced techniques in mitochondrial biology, the company aims to restore proper mitochondrial function and alleviate the symptoms of associated diseases. Their approach focuses on correcting the underlying genetic defects and improving the overall health of mitochondria within cells. This strategy holds the potential to provide disease-modifying treatments for a broad spectrum of mitochondrial disorders.
Target Audience
The primary target audience includes individuals affected by genetic mitochondrial disorders and the healthcare providers who treat them.
Features
- Focus on therapies targeting the root cause of mitochondrial dysfunction.
- Utilizes advanced mitochondrial biology techniques.
- Addresses over 50 diseases linked to genetic mitochondrial disorders.